Wells Fargo Begins Covering uniQure NV (NASDAQ:QURE) Stock. “Shares to Hit $47.0000”

May 16, 2018 - By Vivian Park

uniQure N.V. (NASDAQ:QURE) Logo

Why Has Wells Fargo Given uniQure NV (NASDAQ:QURE) a $47.0000 Price Target

Analysts at Wells Fargo has begun coverage on shares of uniQure NV (NASDAQ:QURE) in analysts note sent to investors and clients on Wednesday morning. The financial company set “Buy” rating on the $1.20 billion market cap company.

uniQure N.V. (NASDAQ:QURE) Ratings Coverage

Among 3 analysts covering uniQure NV (NASDAQ:QURE), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. uniQure NV has $6300 highest and $25.0 lowest target. $42.67’s average target is 31.70% above currents $32.4 stock price. uniQure NV had 5 analyst reports since December 1, 2017 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, March 15 by H.C. Wainwright. Janney Capital maintained uniQure N.V. (NASDAQ:QURE) on Tuesday, March 20 with “Buy” rating. Leerink Swann maintained uniQure N.V. (NASDAQ:QURE) on Monday, May 7 with “Buy” rating. Janney Capital initiated the shares of QURE in report on Wednesday, January 3 with “Buy” rating.

The stock increased 2.82% or $0.89 during the last trading session, reaching $32.4. About 336,178 shares traded. uniQure N.V. (NASDAQ:QURE) has risen 293.97% since May 16, 2017 and is uptrending. It has outperformed by 282.42% the S&P500.

Analysts await uniQure N.V. (NASDAQ:QURE) to report earnings on August, 14. They expect $-0.68 earnings per share, up 18.07 % or $0.15 from last year’s $-0.83 per share. After $-0.59 actual earnings per share reported by uniQure N.V. for the previous quarter, Wall Street now forecasts 15.25 % negative EPS growth.

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company has market cap of $1.20 billion. The companyÂ’s principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It currently has negative earnings. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency.

More notable recent uniQure N.V. (NASDAQ:QURE) news were published by: Benzinga.com which released: “Chardan’s Top Pick For 2018: Gene Therapy Firm Uniqure” on April 24, 2018, also Seekingalpha.com with their article: “Premarket analyst action – healthcare” published on May 16, 2018, Seekingalpha.com published: “Genomic Medicine: Catch The Gene Therapy Wave” on May 14, 2018. More interesting news about uniQure N.V. (NASDAQ:QURE) were released by: Globenewswire.com and their article: “uniQure Announces Proposed Public Offering” published on May 01, 2018 as well as Streetinsider.com‘s news article titled: “Wells Fargo Starts uniQure BV (QURE) at Outperform” with publication date: May 16, 2018.

uniQure N.V. (NASDAQ:QURE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

WP Twitter Auto Publish Powered By : XYZScripts.com